Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 34OTHER 33NIH 8NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1Melanoma 1Glioma 1Brain Neoplasms 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Cisplatin 3X-Rays 2Watchful Waiting 2Vinblastine 2Temozolomide 2Specimen Handling 2Radiotherapy 2Polymerase Chain Reaction 2Observation 2Nivolumab 2Ipilimumab 2Immunologic Techniques 2Flow Cytometry 2trametinib 1sulforaphane 1sargramostim 1romidepsin 1perifosine 1pembrolizumab 1peginterferon alfa-2b 1montanide ISA 51 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Melanoma × dabrafenib × Clear all
NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Canadian Cancer Trials Group

Phase 2 Terminated
6 enrolled 3 charts
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡